Copy
See below for a daily digest of the latest Huntington's Disease news!

Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203

Jun 29, 2017 10:11 am | Joana Fernandes, PhD

 

Huntington's therapy financingMitoconix Bio has secured $20 million in financing to continue developing MTC-1203 as a treatment for mitochondrial impairment in Huntington’s and Parkinson’s diseases. Several pharmaceutical companies and medical-related venture-capital funds participated in the financing. They include Aril Bioscience, OrbiMed, Remiges Ventures and the Dementia Discovery Fund. “We are very excited to complete our financing round with […]

The post Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203 appeared first on Huntington's Disease News.

Read More
share on Twitter Like Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203 on Facebook

Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease

Jun 27, 2017 06:48 am | Carolina Henriques

 

Ionis-HTTRxIonis Pharmaceuticals has completed enrollment of the Phase 1/2a study evaluating the safety, tolerability, properties and movement within the body of Ionis-HTTRx in patients with Huntington’s disease (HD). Patients who complete the randomized, placebo-controlled, dose escalation study (NCT02519036) will be eligible to enroll in an open-label extension trial that should begin in the next few […]

The post Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease appeared first on Huntington's Disease News.

Read More
share on Twitter Like Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease on Facebook

Recent Posts

Researchers Identify Variant in MSH3 Gene Related to Huntington’s Progression
Inhibiting Enzyme Slows Huntington’s Progression in Mice and Lengthens Their Lives, Study Reports
Low Pyk2 Protein Levels May Contribute to Memory Deficits in Huntington’s Disease, Study Shows
Researchers Propose NfL as New Blood Marker of Huntington’s Disease Onset, Progression
Cell Transport ‘Traffic Jam’ Caused by Mutated Protein, Researchers Discover

Copyright © 2017 BioNews Services, LLC, All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences